742560
Last Update Posted: 2018-01-10
Recruiting has ended
All Genders accepted | 18 Years + |
101 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma
The purpose of this study is to evaluate the combination of elotuzumab, lenalidomide, and dexamethasone in subjects with relapsed multiple myeloma.
Eligibility
Relevant conditions:
Hematologic Cancer
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov